SSTR2 and neoplasm: First, GEP-NETs relyon surgery as a critical component of patient care but lack technologies9 that can identify small, multifocal lesions orinvolved lymph nodes, both of which are common in this disease processor tumor margins in the operating room.10−13 Second, these patients are administeredclinically approved radioactive somatostatin analogues for preoperativeimaging and surgical planning via a somatostatinreceptor subtype-2 (SSTR2)-targeted positron emission tomography (PET)scan,14,15 thereby establishing the value of the somatostatinanalogue/SSTR2 ligand-receptor axis.